Hosted on MSN1y
Modifying brain molecule relaxin-3 can potentially reduce side effects in treating anxiety, depression and more
When relaxin-3 is released in the brain, it binds to a target receptor RXFP3—to trigger a variety of signaling responses among the cells, which affect the body's physiological processes.
Business Insider23d
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product ...